Hammer A - Search Results

1

Heart Failure with Preserved Ejection Fraction Correlates with Fibrotic Atrial Myopathy in Patients Undergoing Atrial Fibrillation Ablation.

Lee J, Sponder M, Stojkovic S, Riesenhuber M, Hammer A, Hofbauer TM, Sulzgruber P, Burger S, Kastl S, Duca F, Schönbauer R. Lee J, et al. Among authors: hammer a. J Clin Med. 2024 Sep 24;13(19):5685. doi: 10.3390/jcm13195685. J Clin Med. 2024. PMID: 39407745 Free PMC article.

2

The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report.

Hammer A, Schnaubelt S, Niessner A, Sulzgruber P. Hammer A, et al. Eur Heart J Case Rep. 2020 Sep 9;4(5):1-4. doi: 10.1093/ehjcr/ytaa176. eCollection 2020 Oct. Eur Heart J Case Rep. 2020. PMID: 33204971 Free PMC article.

3

The impact of CD4⁺CD28^null T lymphocytes on atrial fibrillation: a potential pathophysiological pathway.

Hammer A, Niessner A, Sulzgruber P. Hammer A, et al. Inflamm Res. 2021 Dec;70(10-12):1011-1014. doi: 10.1007/s00011-021-01502-w. Epub 2021 Sep 18. Inflamm Res. 2021. PMID: 34536081 Free PMC article.

4

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.

Hammer A, Niessner A, Sulzgruber P. Hammer A, et al. N Engl J Med. 2022 Dec 1;387(22):2100. doi: 10.1056/NEJMc2213437. N Engl J Med. 2022. PMID: 36449435 No abstract available.

5

Rivaroxaban in Valvular Atrial Fibrillation - a Critical Appraisal of the INVICTUS Trial.

Hammer A, Niessner A, Sulzgruber P. Hammer A, et al. Cardiovasc Drugs Ther. 2024 Oct;38(5):1065-1067. doi: 10.1007/s10557-023-07470-z. Epub 2023 May 25. Cardiovasc Drugs Ther. 2024. PMID: 37227566 Free PMC article. Clinical Trial.

6

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?

Hammer A, Niessner A, Sulzgruber P. Hammer A, et al. ESC Heart Fail. 2023 Dec;10(6):3735-3738. doi: 10.1002/ehf2.14549. Epub 2023 Oct 8. ESC Heart Fail. 2023. PMID: 37806673 Free PMC article. No abstract available.

7

The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction.

Hammer A, Sulzgruber P, Koller L, Kazem N, Hofer F, Richter B, Blum S, Hülsmann M, Wojta J, Niessner A. Hammer A, et al. Mediators Inflamm. 2020 Feb 10;2020:6079713. doi: 10.1155/2020/6079713. eCollection 2020. Mediators Inflamm. 2020. PMID: 32104149 Free PMC article.

8

Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Sulzgruber P, Hofer F, Kazem N, Hammer A, Niessner A. Sulzgruber P, et al. Among authors: hammer a. Cardiovasc Drugs Ther. 2021 Aug;35(4):875-876. doi: 10.1007/s10557-021-07165-3. Epub 2021 Mar 4. Cardiovasc Drugs Ther. 2021. PMID: 33661431 No abstract available.

9

Cardiogenic Shock Does Not Portend Poor Long-Term Survival in Patients Undergoing Primary Percutaneous Coronary Intervention.

Steinacher E, Hofer F, Kazem N, Hammer A, Koller L, Lang I, Hengstenberg C, Niessner A, Sulzgruber P. Steinacher E, et al. Among authors: hammer a. J Pers Med. 2022 Jul 22;12(8):1193. doi: 10.3390/jpm12081193. J Pers Med. 2022. PMID: 35893287 Free PMC article.

10

The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome.

Kazem N, Hofer F, Koller L, Hammer A, Hofbauer TM, Hengstenberg C, Niessner A, Sulzgruber P. Kazem N, et al. Among authors: hammer a. Eur Heart J Open. 2021 Oct 27;2(1):oeab031. doi: 10.1093/ehjopen/oeab031. eCollection 2022 Jan. Eur Heart J Open. 2021. PMID: 35919656 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

638 results

Search Page

Filters